Published in Br J Cancer on March 01, 1991
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer (1995) 1.81
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer (1992) 1.62
Bimodal gene expression patterns in breast cancer. BMC Genomics (2010) 1.07
Significance of Her-2/neu protein over expression in Indian breast cancer patients. Indian J Surg (2008) 1.04
Phosphotyrosine signaling proteins that drive oncogenesis tend to be highly interconnected. Mol Cell Proteomics (2013) 0.90
Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates. Br J Cancer (1995) 0.90
Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J Cancer (1992) 0.89
Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma. Br J Cancer (1995) 0.87
Amplification of the MYC Gene in Osteosarcoma Secondary to Paget's Disease of Bone. Sarcoma (1997) 0.84
Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms. Br J Cancer (1994) 0.83
Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer (1993) 0.83
The silent estrogen receptor--can we make it speak? Cancer Biol Ther (2009) 0.79
Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. Br J Cancer (1993) 0.75
Critical determination of the frequency of c-erbB-2 amplification in breast cancer. Br J Cancer (1994) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med (1985) 8.45
A prognostic index in primary breast cancer. Br J Cancer (1982) 7.35
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Confirmation of a prognostic index in primary breast cancer. Br J Cancer (1987) 3.29
Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med (1989) 3.21
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol (1990) 3.12
Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer (1990) 3.01
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res (1989) 2.39
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res (1988) 2.36
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet (1989) 1.77
Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res (1989) 1.58
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer (1988) 1.52
Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res (1989) 1.48
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene (1989) 1.41
c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer (1991) 1.37
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer (1991) 1.35
Proto-oncogene amplification and human breast tumor phenotype. Oncogene (1989) 1.27
Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene (1989) 1.25
An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer (1989) 1.23
Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet (1989) 1.22
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res (1989) 1.19
Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res (1988) 1.10
The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer (1991) 1.04
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res (1989) 1.02
Predictive value of nuclear DNA content in breast cancer in relation to clinical and morphologic factors. A retrospective study of 227 consecutive cases. Cancer (1988) 1.01
c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer (1989) 0.96
c-erbB-2 amplification in node-negative human breast cancer. Cancer Res (1989) 0.94
HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med (1990) 0.91
c-erbB-2 protein expression in node negative breast cancer. Ann Oncol (1990) 0.89
A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene (1989) 0.86
Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer (1990) 0.80
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res (2000) 1.88
Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care. Radiology (2001) 1.85
Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer (1993) 1.48
Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer (2003) 1.23
Feasibility and compliance of automated measurement of quality of life in oncology practice. J Clin Oncol (2003) 1.22
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Sexual activity questionnaires in clinical trials: acceptability to patients with gynaecological disorders. Br J Obstet Gynaecol (1999) 1.17
Supradiaphragmatic manifestations of papillary serous adenocarcinoma of the ovary. Clin Radiol (1999) 1.16
The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer (1993) 1.15
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol (1996) 1.14
Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. Int J Cancer (1998) 1.12
Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol (1987) 1.11
Combination of bleomycin and mitomycin after failure of cisplatin and alkylating agent therapy in epithelial ovarian cancer. Cancer Treat Rep (1986) 1.08
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer (1989) 1.03
Effects of interleukin 6 administration on platelets and haemopoietic progenitor cells in peripheral blood. Cytokine (1996) 1.02
Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. BJOG (2007) 1.00
The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol (1995) 0.95
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer (1990) 0.92
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer (1988) 0.91
Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis. Int J Gynecol Cancer (2006) 0.89
Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer? Br J Cancer (2002) 0.89
Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer (2004) 0.86
Gastroduodenal obstruction from ovarian cancer: imaging features and clinical outcome. Clin Radiol (2000) 0.84
The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer (1989) 0.84
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol (1990) 0.84
Metastatic breast carcinoma involving the gastric antrum and duodenum: computed tomography appearances. Br J Radiol (1995) 0.81
Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann Oncol (1991) 0.81
A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH. Clin Endocrinol (Oxf) (1985) 0.80
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Br J Cancer (1997) 0.80
A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer. Clin Oncol (R Coll Radiol) (1996) 0.79
Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: the ITS Study. Br J Cancer (2007) 0.79
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine (2000) 0.78
Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group. Cancer Chemother Pharmacol (1990) 0.77
A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy. Cancer Chemother Pharmacol (1988) 0.77
Anthracycline-induced cardiomyopathy in siblings with early breast cancer. Ann Oncol (2011) 0.77
CT appearances and prognostic significance of splenic metastasis in ovarian cancer. Clin Radiol (1998) 0.77
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests. Hematol Oncol (2000) 0.76
Phospholipase A2 activity in serum is induced during treatment with recombinant human interleukin-6 in patients with cancer. Ann Clin Biochem (1996) 0.76
Encephalopathy with rapid infusion ifosfamide/mesna. Lancet (1987) 0.75
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. Br J Cancer (2004) 0.75
Adjuvant therapy for operable breast cancer; more answers, new questions. Br J Cancer (1995) 0.75
CT demonstration of calcified metastatic mediastinal lymph nodes. Clin Radiol (1998) 0.75
Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity. Invest New Drugs (1985) 0.75
Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Cancer Chemother Pharmacol (1986) 0.75
Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival. Br J Urol (1987) 0.75
Assessment of bleomycin, adriamycin and mitomycin-C in the treatment of recurrent cervical cancer. Br J Obstet Gynaecol (1985) 0.75